Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...
November 06, 2025 07:01 ET | Source: Climb Bio, Inc.

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical...
November 03, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...
October 21, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...
October 17, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up...
October 01, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...
September 29, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with...
September 04, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today...
August 25, 2025 14:41 ET | Source: Climb Bio, Inc.

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...
August 25, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio to Present at Upcoming September 2025 Investor Conferences

WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...